- Home
- QNRX vs CWD Comparison
QNRX vs CWD Comparison
Compare QNRX & CWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNRX
- CWD
- Stock Information
- Founded
- QNRX 2018
- CWD 2009
- Country
- QNRX United States
- CWD United States
- Employees
- QNRX N/A
- CWD N/A
- Industry
- QNRX Medical/Dental Instruments
- CWD Real Estate
- Sector
- QNRX Health Care
- CWD Finance
- Exchange
- QNRX Nasdaq
- CWD Nasdaq
- Market Cap
- QNRX 4.3M
- CWD 4.5M
- IPO Year
- QNRX N/A
- CWD 2023
- Fundamental
- Price
- QNRX $7.20
- CWD $1.70
- Analyst Decision
- QNRX
- CWD
- Analyst Count
- QNRX 0
- CWD 0
- Target Price
- QNRX N/A
- CWD N/A
- AVG Volume (30 Days)
- QNRX 4.5K
- CWD 4.8M
- Earning Date
- QNRX 08-07-2025
- CWD 08-13-2025
- Dividend Yield
- QNRX N/A
- CWD N/A
- EPS Growth
- QNRX N/A
- CWD N/A
- EPS
- QNRX N/A
- CWD N/A
- Revenue
- QNRX N/A
- CWD $32,323,000.00
- Revenue This Year
- QNRX N/A
- CWD N/A
- Revenue Next Year
- QNRX N/A
- CWD $31.12
- P/E Ratio
- QNRX N/A
- CWD N/A
- Revenue Growth
- QNRX N/A
- CWD N/A
- 52 Week Low
- QNRX $5.01
- CWD $1.63
- 52 Week High
- QNRX $54.95
- CWD $15.80
- Technical
- Relative Strength Index (RSI)
- QNRX 43.44
- CWD 32.57
- Support Level
- QNRX $7.05
- CWD $1.63
- Resistance Level
- QNRX $7.30
- CWD $1.95
- Average True Range (ATR)
- QNRX 0.33
- CWD 0.68
- MACD
- QNRX 0.05
- CWD -0.06
- Stochastic Oscillator
- QNRX 41.14
- CWD 1.04
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
About CWD CaliberCos Inc.
CaliberCos Inc is an asset management firm whose primary goal is to enhance the wealth of investors seeking to make investments in middle-market assets. The company's funds include investment vehicles focused on real estate, private equity, and debt facilities. The company earns asset management fees calculated as a percentage of managed capital in funds and offerings. The company markets services through direct sales to private investors, wholesaling to investment advisers, direct sales to family offices and institutions and through in-house client services. The company operates into three reportable segments: Fund Management, Development, and Brokerage. The majority of revenue is derived from the fund management fees segment.